The Impact of the COVID-19 Pandemic on Respiratory Syncytial Virus Infection: A Narrative Review
Yu-Chuan Chuang,Kuan-Pei Lin,Li-An Wang,Ting-Kuang Yeh,Po-Yu Liu
DOI: https://doi.org/10.2147/IDR.S396434
2023-01-31
Infection and Drug Resistance
Abstract:Yu-Chuan Chuang, 1 Kuan-Pei Lin, 1 Li-An Wang, 1 Ting-Kuang Yeh, 2, 3 Po-Yu Liu 2– 6 1 Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 2 Division of Infectious Disease, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 3 Genomic Center for Infectious Diseases, Taichung Veterans General Hospital, Taichung, Taiwan; 4 Ph.D. in Translational Medicine, National Chung Hsing University, Taichung, Taiwan; 5 Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan; 6 Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan Correspondence: Po-Yu Liu, Division of Infectious Disease, Department of Internal Medicine, Taichung Veterans General Hospital, No. 1650, Sec. 4, Taiwan Blvd., Xitun Dist, Taichung City, 407219, Taiwan, Tel +886 4 2359 2525, Email Respiratory syncytial virus (RSV) is one of the most common respiratory viruses. It not only affects young children but also the elderly and immunocompromised patients. After the emergence of SARS-CoV-2 and the corona virus disease 2019 (COVID-19) era, a dramatic reduction in RSV activity was found, which coincided with the implementation of public health and social measures (PHSMs). However, the correlation is more complicated than we initially thought. After PHSMs were gradually lifted, a seasonality shift and a delayed RSV outbreak with greater number of infected patients were found in numerous countries, such as Israel, Australia, South Africa, New Zealand, France, United States, and Japan. Several hypotheses and possible reasons explaining the interaction between SARS-CoV-2 and RSV were mentioned. Since RSV vaccinations are still under investigation, administration of palivizumab should be considered in high-risk patients. In the post-COVID-19 era, greater attention should be paid to a further resurgence of RSV. In this narrative review, we conducted a thorough review of the current knowledge on the epidemiology of RSV during the COVID-19 era, the out-of-season outbreak of RSV, and the data on co-infection with RSV and SARS-CoV-2. Keywords: COVID-19 pandemic, SARS-CoV-2, respiratory syncytial virus, influenza virus, respiratory tract infection RSV belongs to the Pneumoviridae family, which is a single-stranded and negative-sense RNA virus. RSV can be grouped according to two main antigens, known as A and B subtypes. 1 Respiratory syncytial virus (RSV) is one of the most common respiratory viruses. It not only affects young children but also the elderly and immunocompromised patients. The elderly, patients with particular comorbidities, such as chronic lung disease, those who have undergone transplantation, and immunocompromised patient are more vulnerable to severe RSV infection. 2 In temperate countries, RSV is predominant in winter. In comparison, outbreaks of RSV may be observed during cooler months or wet months in tropical and sub-tropical countries. 3,4 RSV infection has become a major public healthcare issue, which has caused significant hospitalization and mortality rates, partially due to the lack of vaccination against RSV. 5 During the corona virus disease 2019 (COVID-19) era, clinicians and researchers have noted similarities and differences between RSV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 era has seen the widespread implementation of public health and social measures (PHSMs), which include personal protective measures, such as mask-wearing, hand hygiene, and social distancing, environmental measures, and surveillance and response measures. 6 PHSMs play an indispensable role against SARS-CoV-2 transmission. The implemented PHSMs have simultaneously had an enormous impact on other respiratory viral diseases. Many studies have shown a remarkable decrease in the incidence of RSV and other common respiratory pathogens during the COVID-19 era. 7 However, while it appears that there is a simple direct correlation, the true nature of the relationship may be more complicated. When PHSMs were gradually lifted, a seasonality shift and a delayed RSV outbreak with greater number of infected patients were found in a number of countries, such as Israel, Australia, South Africa, New Zealand, France, United States, and Japan. 8,9 Delayed outbreaks also caused a higher hospitalization rate, even though the clinical symptoms seemed to be milder. 10 Therefore, it is important to pay attention to and prepare well for the possibility of further out-of-season RSV peaks. 9 The symptoms caused by SARS-CoV-2 may be difficult to differentiate fro -Abstract Truncated-
pharmacology & pharmacy,infectious diseases